Source comparison
MOTS-c Research Protocols: Comparison of Dosing and Application Methods
USC Rodent Metabolic Study (2015) 5mg per injection (scaled to body weight) 3× weekly for 8 weeks Insulin sensitivity, treadmill endurance time Demonstrated proof-of-concept for metabolic benefit. Human equivalent doses remain unvalidated Kumamoto University A
This comparison does not assign a generated winner or score.
- USC Rodent Metabolic Study (2015)
- 5mg per injection (scaled to body weight)
- 3× weekly for 8 weeks
- Insulin sensitivity, treadmill endurance time
- Demonstrated proof-of-concept for metabolic benefit. Human equivalent doses remain unvalidated
- Kumamoto University Aging Study (2021)
- 5mg per injection
- 3× weekly for 12 weeks
- Mitochondrial respiration capacity, running endurance
- Showed restoration of age-related decline. Suggests potential for masters athletes but lacks human trial data
- Anecdotal Athlete Protocols (2024–2026)
- 5–15mg total weekly
- 2–3× weekly aligned with key workouts
- Subjective recovery, perceived exertion during long runs
- Reported improvements in metabolic fatigue resistance. No controlled blinding or placebo comparison
- Phase I Human Safety Trials (ongoing as of 2026)
- 0.5–2mg/kg body weight
- Variable. Protocol-dependent
- Safety markers, adverse event tracking
- Establishes tolerability. Performance endpoints not yet assessed in published trials